Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvacta Group Regulatory News (AVCT)

Share Price Information for Avacta Group (AVCT)

Share Price is delayed by 15 minutes
Get Live Data
71.50    1.50 (2.14%)
Bid:
71.00
Ask:
72.00
Spread: 1.00 (1.408%)
Market Cap: £325.40m
AVCT Live PriceLast checked at - London Stock Exchange

Intraday Avacta Group Share Chart

Directorate Appointment

9 Nov 2007 16:59

Avacta Group plc Board Appointment

Avacta Group plc ("Avacta" or the "Company"), which develops detection and analysis technology aimed at the biopharmaceutical, defence & security and clinical diagnostics markets, is pleased to announce the appointment of Russell Hodgetts to the Board of Directors, with effect from 10 July 2007.

Russell Winston Hodgetts, 36, has been Chief Operating Officer of Avacta since October 2005, and has a wealth of experience in strategic business development and group operations. Prior to joining Avacta he worked for Techtran Group Limited where he helped guide the commercialization and business development of companies created from University of Leeds research and intellectual property.

He currently oversees the development of the analytical services division of the Company in addition to being responsible for group operations.

Russell Hodgetts is the beneficial owner of 9,847,912 ordinary shares of 0.1p each in the capital of the Company ("Ordinary Shares"), representing approximately 1.27 per cent. of the issued share capital of the Company and 1,804,568 options to acquire Ordinary Shares at an exercise price of 2.25p per share.

He is also a director of Avacta Analytical Limited.

Russell Hodgetts was named Russell Beckett until family circumstances led to his name being changed when aged 11.

There are no other disclosures required by paragraph (g) of Schedule 2 of the AIM Rules for Companies.

Professor Alastair Smith, Chief Executive, Avacta Group plc, commented:

"Russell has been an integral part of the development of Avacta over the past two years and his focus on continued growth has been central to the success of Avacta Analytical Ltd. We are pleased to welcome him to the Board and will continue to draw on his knowledge and drive to ensure that Avacta maintains its current path of development and innovation."

9 November 2007EnquiriesAvacta Group plc Tel: 0870 835 4367 Alastair Smith, Chief Executive WH Ireland Limited Tel: 0161 832 2174 David Youngman/Robin Gwyn BankOra Limited Tel: 020 7562 4713 Henry Turcan/Michael Brennan Nexus Financial Ltd Tel: 020 7451 7050 Nicholas Nelson/Kathy Boate nicholas.nelson@nexusgroup.co.uk

AVACTA GROUP PLC
Date   Source Headline
5th Sep 20187:00 amRNSNotice of Results
31st Aug 20189:55 amRNSHolding(s) in Company
23rd Aug 20185:07 pmRNSHolding(s) in Company
23rd Aug 20185:06 pmRNSHolding(s) in Company
23rd Aug 201811:21 amRNSHolding(s) in Company
22nd Aug 20182:23 pmRNSHolding(s) in Company
22nd Aug 20189:20 amRNSHolding(s) in Company
17th Aug 201811:30 amRNSResult of General Meeting
6th Aug 20184:24 pmRNSHolding(s) in Company
30th Jul 20186:06 pmRNSResults of Placing and Subscription
30th Jul 201811:41 amRNSProposed Placing and Subscription to raise £11.4m
30th Jul 201810:35 amEQSHardman & Co Research: Avacta (AVCT): Ground-breaking new drug conjugate platform
24th Jul 20187:00 amRNSMajor Therapeutics Co-development Partnership
26th Jun 20181:30 pmEQSHardman & Co Research: Avacta (AVCT): Gearing up the management team
11th Jun 20187:00 amRNSAppointment of Non-Executive Chairman
31st May 201812:15 pmEQSHardman & Co Research: Avacta (AVCT): In vivo expression of Affimers
22nd May 20187:00 amRNSSuccessful Outcome of Study with FIT Biotech
30th Apr 20184:45 pmRNSHolding(s) in Company
17th Apr 20187:17 amEQSHardman & Co Research: Avacta (AVCT): Commendable rate of progress
16th Apr 20187:25 amRNSInterim Results
9th Apr 20182:58 pmRNSIssue of Equity
29th Mar 20187:00 amRNSAvacta to Present at Investor Forum
29th Mar 20187:00 amRNSDirectorate Change
13th Mar 201812:02 pmRNSDirector/PDMR Shareholding
7th Mar 20184:35 pmRNSPrice Monitoring Extension
8th Feb 20187:00 amRNSSummary of Capital Markets Day
22nd Jan 20187:00 amRNSAvacta and OncoSec to Collaborate
18th Jan 201811:26 amRNSResult of Annual General Meeting
18th Jan 20187:00 amRNSAGM Business Update and Notice of Results
15th Jan 201810:58 amRNSHardmanResearch: Affimer Drug Conjugates a reality
15th Jan 20187:00 amRNSDrug Development Partnership with Glythera
8th Jan 20187:00 amRNSCapital Markets Day Notification
4th Jan 201811:04 amRNSPDMR Dealing and Issue of Equity
3rd Jan 20187:00 amRNSPresenting at the Biotech Showcase, San Francisco
18th Dec 20174:28 pmRNSIssue of Equity
4th Dec 201711:03 amRNSPosting of Annual Report and Notice of AGM
30th Nov 201710:57 amRNSIssue of Equity
15th Nov 20177:00 amRNSCovance to Present Affimer Data at Conference
14th Nov 20173:27 pmRNSHolding(s) in Company
13th Nov 20177:00 amRNSAvacta to Present at Investor Evening
13th Nov 20177:00 amRNSAvacta to present at PEGS Europe
24th Oct 20177:00 amRNSAffimers in Scientific Publications
19th Oct 20177:00 amRNSPrivate Shareholder Update Event
16th Oct 201710:42 amRNSHardman Res.: R&D accelerated to advance assets
12th Oct 20177:00 amRNSAvacta to Present at Shares Spotlight Evening
10th Oct 20177:00 amRNSAvacta to Present at Major US Conference
9th Oct 20174:02 pmRNSDirector Dealing and Issue of Equity
5th Oct 20177:00 amRNSResearch collaboration with FIT Biotech Oy
4th Oct 20177:00 amRNSPreliminary Results
2nd Oct 20177:00 amRNSAvacta establishes US business development team

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.